氨基酸输注时长与肾脏保护:PROTECTION 试验二次分析
该研究为 PROTECTION 随机双盲安慰剂对照试验的事后二次分析,纳入 3481/3511 例心脏手术成人患者,比较短期(≤48 h)与延长(>48 h 但 ≤72 h)氨基酸输注对急性肾损伤(AKI)和 ICU 死亡率的影响。结果显示两组对 AKI 的效应方向一致(交互 P=0.89),但短期输注降低肾替代治疗使用且 ICU 死亡率由 1.9% 降至 1.0%,延长输注则死亡率由 2.5% 升至 3.5%(交互 P=0.04)。
要点
- 短期与延长氨基酸输注对 AKI 的效应方向一致(交互 P=0.89)。
- 短期输注降低肾替代治疗使用,延长输注无此效应。
- 短期输注降低 ICU 死亡率,延长输注反而升高(交互 P=0.04)。
核心结论
- 氨基酸对 AKI 的效应在短期与延长输注亚组间一致,但对生存的效应方向相反,且有利于短期输注组。
- 结果仅为假设生成性,遵循欧洲指南和 PROTECTION 试验结果并在临床实践中实施氨基酸的中心应考虑输注时长 ≤48 h。
研究设计与样本
- PROTECTION 随机双盲安慰剂对照试验的事后二次分析(ClinicalTrials.gov NCT03709264)。
- 将患者分为短期(≤48 h)或延长(>48 h 但 ≤72 h)氨基酸输注组,3481/3511 例患者有可用数据。
主要发现
- 短期与延长氨基酸输注对 AKI 的效应幅度和方向相似(交互 P=0.89),风险降低分别为 3.8%(25% 至 21%)和 5.7%(44% 至 38%)。
- 短期氨基酸输注显示肾替代治疗使用减少,而延长输注无效应。
- 氨基酸对 ICU 死亡率的影响不一致:短期输注组从 1.9% 降至 1.0%,延长输注组从 2.5% 升至 3.5%(交互 P=0.04)。
临床怎么用
- 遵循欧洲指南和 PROTECTION 试验结果并在临床实践中实施氨基酸的中心应考虑氨基酸输注时长 ≤48 h。
局限性
- 结果为假设生成性(hypothesis generating)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intravenous amino acids (AA) reduce acute kidney injury (AKI) in adult patients undergoing cardiac surgery. Because the optimal duration of AA infusion is unknown, we investigated the effect of AA infusion duration on AKI and survival. METHODS: In a secondary post hoc analysis of the PROTECTION randomised double-blind placebo-controlled trial, we divided patients into brief (≤48 h) or prolonged (>48 h but ≤72 h) AA infusion. The primary objective was to assess whether the direction of the effects on AKI and ICU mortality was consistent across subgroups. RESULTS: A total of 3481/3511 patients had available data. Brief and prolonged AA infusion had similar magnitude and direction of effect on AKI (interaction P=0.89), with a risk reduction of 3.8% (25% to 21%) and 5.7% (44% to 38%), respectively. Brief AA infusion showed a reduction in the use of renal replacement therapy, whereas prolonged infusion showed no effect. The effects of AA on intensive care unit mortality were discordant (a reduction from 1.9% to 1.0% in the brief infusion group, and an increase from 2.5% to 3.5% in the prolonged infusion group; interaction P=0.04). CONCLUSIONS: The effect of AA on AKI was consistent across subgroups, whereas they had opposing effects on survival in patients receiving brief or prolonged study drug infusion and in favour of the brief infusion group. Although these results are hypothesis generating, centres that are following European guidelines and PROTECTION trial results and are implementing AA in clinical practice should consider AA infusion lasting ≤48 h. CLINICAL TRIAL REGISTRATION: NCT03709264.
引用
- Landoni G, Oriani A, Ti LK, et al. Association of duration of amino acids infusion and renal protection: a secondary analysis of the PROTECTION trial. Br J Anaesth. 2026. PMID: 41741282. doi:10.1016/j.bja.2025.12.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。